ADC Therapeutics SA · NYSE:ADCT
ADC Therapeutics SA — Corporate Update (November 2026)
18 slides from ADC Therapeutics SA's corporate update, Nov 4, 2026
Slide 1: Corporate Webcast ASH Abstract Update
Corporate Webcast ASH Abstract Update November 4, 2026
Slide 2: Agenda
Agenda 02 03 ASH Abstract Highlights Mohamed Zaki Chief Medical Officer Financial Update Pepe Carmona Chief Financial Officer 01 Introduction Ameet Mallik Chief Executive Officer 04 Q&A
Slide 3: Forward-Looking Statements
ADC Therapeutics | 3 Forward - Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose . Nothing contained in this presentation is, or should
Slide 4: Value Drivers Supported by a Strong Balance Sheet
Value Drivers Supported by a Strong Balance Sheet Approved product 2L+ DLBCL LOTIS - 7: ZYNLONTA plus glofitamab MZL IIT: ZYNLONTA monotherapy Strong balance sheet provides broader strategic optionality
Slide 5: Key Business Updates
Key Business Updates ASH Data Highlights Breadth of ZYNLONTA® Clinical Program with 5 oral presentations: ▪ Phase 1b LOTIS - 7 abstract data demonstrating potentially best - in - class efficacy with an 88.7% ORR and 75.3% CR across the 97 efficacy - evaluable patients ▪ Robust and durable 93% ORR an
Slide 6: LOTIS-7 Phase 1b Trial: Response
• In patients with primary refractory disease (n=54): an ORR of 78.4% and CRR of 64.7% were observed • Among patients with prior CAR - T exposure (n=28): an ORR of 74.1% and CRR of 63.0% were observed • In an exploratory MRD analysis of 12 patients achieving CR: 50% achieved undetectable MRD (uMRD)
Slide 7: LOTIS-7: Continues to Demonstrate Manageable Safety Profile
ADC Therapeutics | 7 LOTIS - 7: Continues to Demonstrate Manageable Safety Profile r/r Large B - Cell Lymphoma all ZYNLONTA Treated Population* (N=103) at ZYNLONTA 150 µg/kg starting dose in Parts 1 and 2, as of Data Cutoff of June 15, 2026 Combination generally well tolerated with a manageable safe
Slide 8: ZYNLONTA in 2L+ MZL: Phase IIT Updated Efficacy Overview
ADC Therapeutics | 8 ZYNLONTA in 2L+MZL: Phase 2 IIT Updated Efficacy Overview Updated results as of data cutoff of July 1, 2026 Source: ASH Abstract submitted on Aug 4, 2026 by Dr. I. Lossos, University of Miami (as of July 1, 2026) Note: N=43 patients who were efficacy evaluable , N=47 patients en
Slide 9: ZYNLONTA in 2L+ MZL: Phase IIT Updated Safety Overview
ADC Therapeutics | 9 ZYNLONTA in 2L+ MZL: Phase 2 IIT Updated Safety Overview Updated data as of July 1, 2026 cutoff suggest manageable safety generally consistent with known profile of ZYNLONTA Adverse events were most commonly grade 1 or 2 Most common G1 - 2 events were abnormal LFTs (28), rash (1
Slide 10: LOTIS-5: Confirmatory Phase Trial Met Primary Endpoint, Grade 5 Safety Imbalance
ADC Therapeutics | 10 LOTIS - 5: Confirmatory Phase 3 Trial Met Primary Endpoint, However, Grade 5 Safety Imbalance Observed Between Arms R - GemOx,% ZYNLONTA + rituximab, % Event - free rate (95% CI) 38.9 (31.4, 46.3) 50.4 (43.0, 57.3) 6M 23.7 (17.2, 30.8) 29.6 (22.9, 36.5) 12M 14.7 (9.2, 21.5) 25.
Slide 11: ZYNLONTA Consolidation in r/r Mantle Cell Lymphoma
ADC Therapeutics | 11 Initial Data Show Promising ZYNLONTA Activity as Consolidation Following Traditional Chemotherapy in r/r Mantle Cell Lymphoma Oral presentation announced for Investigator - initiated Phase II trial at ASH 2026 COLUMN (N=49) Fondazione Italiana Linfomi (FIL) - Data cutoff July 1
Slide 12: ZYNLONTA in Waldenström Macroglobulinemia (WM-NET1)
ZYNLONTA is currently included in NCCN guidelines for 2L+ WM as category 2A, “useful in certain circumstances” ADC Therapeutics | 12 WM - NET1 (N=20) Dana - Farber, Mass General, Mayo Clinic, Fred Hutch – April 2026 High ORR in heavily pre - treated patients (ORR 90% and VGPR/CR 60%) (median 4 prior
Slide 13: ASH 2026 Oral Presentation Schedule
Type Title Presentation Time Date Oral #238 Loncastuximab tesirine consolidation after short - course R - BAC induction in BTKi - exposed R/R mantle cell lymphoma : Primary endpoint analysis from the phase II column trial from fondazione italiana linfomi (FIL) 2:45 PM - 3:00 PM Saturday, December 12
Slide 14: Comprehensive Strategic Financial Restructuring
14 Comprehensive Strategic Financial Restructuring Strengthened balance sheet, reduced leverage, and increased strategic optionality → $86.6M Private Placement announced extending expected cash runway into 2029 – Included new (Bain Capital Life Sciences), existing (Redmile, TCGX, Nantahala Capital)
Slide 15: Selected Financial Data (Preliminary)
15 Selected Financial Data (Preliminary) For the quarter ended September 30, 2026 All figures reflect in USD M Expected Net Product Revenue – Q3 Expected Cash Balance 16 21 2025 2026 +5 51 60 2025 2026 +8 QTD YTD Increase in Product Revenues, net from sales of ZYNLONTA in the quarter and year - to -
Slide 16: Expanding the ZYNLONTA Franchise
ADC Therapeutics | 16 Expanding the ZYNLONTA Franchise Advancing Into Earlier - Line DLBCL and Indolent Lymphomas Indication Regimen (Target) Trial Phase of Development Status / Next Milestone 3L+ DLBCL ZYNLONTA Monotherapy LOTIS - 2 Mkt ▪ FDA accelerated approval in 2021 ▪ Commercially available 2L
Slide 17: Key Near-Term Anticipated Milestones
ADC Therapeutics | 17 Key Near - Term Anticipated Milestones FDA engagement regarding ZYNLONTA + glofitamab Phase 3 study design Q4 2026 LOTIS - 7 Ph1b & MZL IIT updated data ASH presentations 1H 2027 LOTIS - 7 compendia inclusion MZL IIT Breakthrough Designation submission 2H 2027 Ph3 initiation fo
Slide 18: Thank You
Thank You ® THERAPEUTICS Innovating Science. inspiring Hope.